Effects of nicorandil on myocardial infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: study design and protocol for the randomized controlled trial

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Previous studies have shown that nicorandil has a protective effect on cardiomyocytes. However, there is no study to investigate whether perioperative intravenous nicorandil can further reduce the myocardial infarct size in patients with ST-segment elevation myocardial infarction (STEMI) compared to the current standard of percutaneous coronary intervention (PCI) regimen. The CHANGE (China-Admini stration of Nicorandil Group) study is a multicenter, prospective, randomized, double-blind and parallel-controlled clinical study of STEMI patients undergoing primary PCI in China, aiming to evaluate the efficacy and safety of intravenous nicorandil in ameliorating the myocar dial infarct size in STEMI patients undergoing primary PCI and provide evidence-based support for myocardial protection strategies of STEMI patients.

Related collections

Most cited references 13

Record: found
Abstract: found
Article: found

Is Open Access

China cardiovascular diseases report 2018: an updated summary

Li-Yuan Ma, Wei-Wei Chen, Run-Lin Gao … (2020)

1 Introduction Rapid socioeconomic progress has greatly affected the lifestyle in China. Consequently, owing to lifestyle changes, urbanization, and accelerated population aging, the risk of cardiovascular diseases (CVD) has increased. The incidence of CVD has been increasing continuously and this upward trend is projected to continue in the next decade. The growing burden of CVD has become a major public health issue. Accordingly, since 2005, the National Center for Cardiovascular Diseases of China has directed experts in cardiology, neurology, nephrology, diabetes, epidemiology, community healthcare, health economics, biostatistics, and other related fields to prepare the annual Report on Cardiovascular Diseases in China. This report aims to provide a timely review of the growing epidemic of CVD in the country as well as to assess the progress made in its prevention and control. We present herein an updated summary of the Report on Cardiovascular Diseases in China 2018 that includes trends in CVD, the morbidity and mortality of CVD, risk factor assessment, health resources for CVD, and a profile of medical expenditure. 2 Cardiovascular disease prevalence and mortality The prevalence of CVD in China has been increasing continuously since 2006. Of the approximately 290 million patients with CVD, 13 million, 11 million, 5 million, 4.5 million, 2.5 million, 2 million, and 245 million have stroke, coronary heart disease (CHD), pulmonary heart disease, heart failure (HF), rheumatic heart disease, congenital heart disease, and hypertension, respectively. With respect to mortality, two in five deaths in China are attributed to CVD (Figures 1 & 2), higher than the death rate due to cancer or other diseases. CVD remained the leading cause of death in 2016, accounting for 45.50% and 43.16% of all deaths in rural and urban areas, respectively. Further, from 2009 onwards, the CVD mortality rate in rural areas exceeded that in urban areas, and in 2016, the rate was 309.33 per 100,000 people in rural areas and 265.11 per 100,000 people in urban areas (Figure 3). Figure 1. Major causes of death in the rural Chinese population in 2016. Figure 2. Major causes of death in the urban Chinese population in 2016. Figure 3. Mortality rates due to cardiovascular disease in urban and rural areas in China: 1990–2016. 3 Risk factors of cardiovascular diseases 3.1 Hypertension Data from four national surveys on hypertension showed that the prevalence of hypertension in China among individuals aged over 15 years continuously increased from 5.1% in 1958–1959 to 7.7% in 1979–1980, 13.6% in 1991, and 17.6% in 2002. The Survey on the Status of Nutrition and Health of the Chinese People in 2012 showed that 25.2% of adults in China aged ≥ 18 years had hypertension. Using data from the 2010 National Population Census as a denominator, we can estimate that this corresponded to approximately 270 million individuals. The China Hypertension Survey examined 451,755 individuals aged ≥ 18 years from 262 urban and rural areas in 31 provinces, municipalities, and autonomous regions of mainland China in 2012–2015. Using stratified multi-stage random sampling, they found a 27.9% (weighted: 23.2%) overall crude prevalence of hypertension. Further, they found that hypertension was more prevalent in men than in women (crude rate: 28.6% vs. 27.2%, weighted rate: 24.5% vs. 21.9%), and the prevalence increased with age.[1] Further, this data showed that among Chinese residents aged ≥ 18 years, the overall crude prevalence of high-normal blood pressure was 39.1% (weighted rate: 41.3%). The rates of hypertension awareness, treatment, and control among Chinese adults aged ≥18 years were 51.6%, 45.8% and 16.8%, respectively, and the rate of controlled hypertension among those receiving treatment was 37.5%, higher than the rates observed in previous studies. The results of the China Health and Nutrition Survey (CHNS) showed that the prevalence of hypertension among juveniles markedly increased from 10% in 1993 to 12.9% in 2011, with an average annual increase of 0.16%. Blood pressure levels increased among all groups of children, irrespective of age or sex. In an analysis of 190,000 Han school-age children (7 to 17 years) by the National Student Health Study in 2010, hypertension was found to be present in 14.5% of children and adolescents (boys: 16.1%; girls: 12.9%).[2] A retrospective analysis of hospitalized patients revealed that most children with hypertension (52.0%–81.5%) were admitted for secondary hypertension, and renal hypertension was the leading etiology for secondary hypertension. 3.2 Smoking Since 1984, China has had one of the highest worldwide rates of smoking among men, with the rate having remained above 50% since 1996. A 2015 survey on tobacco-smoking among adults in China showed that the smoking rate among males remained high at 52.1% in those over 15 years of age, although a declining trend since 1996 was observed. In 2002–2010, the annual decline in the normalized smoking rate was 0.08% on average. The Global Youth Tobacco Survey-China, which examined 155,117 students aged 13–15 years in 2014, reported that 6.9% of Chinese teenagers were current smokers. The prevalence was higher in men than in women (11.2% vs. 2.2%) and higher in rural areas than in urban areas (7.8% vs. 4.8%). According to the Global Adult Tobacco Survey in 2010, approximately 738 (72.4%) million non-smokers in China were exposed to secondhand smoke (SHS). However, the proportion of non-smokers who witnessed smoking in indoor workshops, public places, public transport vehicles, and at homes decreased in 2015, indicating that SHS exposure had reduced. The rate of smoking cessation among Chinese individuals aged ≥ 15 years increased from 9.42% in 1996 to 16.9% in 2010. In 2015, it was found that 18.7% of all former and current smokers had become non-smokers. According to the 2104 China Youth Tobacco-smoking Survey of Chinese teenagers, among current smokers, 71.8% had attempted to quit smoking. 3.3 Dyslipidemia The China Chronic Disease and Risk Factor Surveillance (CCDRFS) study examined 163,641 adults from 31 provinces, municipalities, and autonomous regions in China during 2013–2014. The average levels of serum total cholesterol (TC), low-density lipoprotein cholesterol, triglyceride, and high-density lipoprotein cholesterol among Chinese individuals aged ≥ 18 years were 4.70, 2.88, 1.14, and 1.35 mmol/L, respectively.[4] The level of serum TC observed was significantly higher than that noted in the 2002 CHNS (3.81 mmol/L) and 2010 CCDRFS (4.04 mmol/L). Data from the CHNS, Chinese National Survey of Chronic Kidney Disease (CNSCKD), and Report on the Nutrition and Chronic Disease Status of Chinese Residents (2015) showed that the prevalence of dyslipidemia in Chinese individuals aged ≥ 18 years increased substantially during the last decade, from 18.6% in 2002 to 34.0% in 2010 and 40.4% in 2012. The 2010 CNSCKD, a cross-sectional study of 43,368 urban and rural residents from 13 provinces and municipalities in mainland China,[4] showed that the rates of dyslipidemia awareness, treatment, and control among people aged ≥ 18 years were 31.0%, 19.5%, and 8.9%, respectively. These rates were also lower in men than in women (30.12% vs. 31.84%, 18.90% vs. 20.01%, and 7.27% vs. 9.62%, respectively). 3.4 Diabetes According to a nationwide epidemiological study performed in 2013, the overall standardized prevalence of diabetes in Chinese adults was approximately 10.9%, and the rate was slightly higher in men than in women (11.7% vs. 10.2%). When diabetes was diagnosed according to hemoglobin A1c (HbA1c) concentration was considered, the prevalence increased by 0.5%. Prediabetes was prevalent in approximately 35.7% of individuals. Among those with diabetes, 36.5% were aware of their condition, 32.2% were treated, and 49.2% of the treated patients had adequate glycemic control.[5] The China Kadoorie Biobank (CKB) was a 7-year nationwide prospective study of 512,869 adults aged 30–79 years.[6] The results showed that adults with diabetes had a significantly higher risk of all-cause mortality than those without diabetes. The presence of diabetes was associated with increased mortality from ischemic heart disease and stroke. Similarly, diabetes was associated with an increased relative risk of mortality from chronic liver disease; infections; and cancer of the liver, pancreas, female breast, and female reproductive system. The increase in mortality due to CVD was the most prominent. Aside from the low treatment and control rates of diabetes, the low use of cardio-protective medications also contributed to the high cardiovascular mortality in patients with diabetes. The CKB estimated that there was a median loss of 9 (rural 10, urban 8) years of life for individuals with diabetes diagnosed before the age of 50 years. 3.5 Overweight and obesity Data from the Report on the Nutrition and Chronic Disease Status of Chinese Residents (2015) demonstrated that in 2012, 30.1% of Chinese residents aged ≥ 18 years were overweight and 11.9% were obese. This increased by 7.3% and 4.8%, respectively, compared with the prevalence in 2002. Although the rates of overweight and obesity in 2012 were lower among rural residents, the increase observed was higher than that in their urban counterparts. The mean waist circumference and the prevalence of abdominal obesity also increased among Chinese adults. Here too, the increase was greater in rural residents, indicating a decrease in the disparity between the two populations. The prevalence of overweight and obesity also increased in children (0–17 years) in both urban and rural areas, with the rate being significantly higher in 2012 than that in 2002. The National Physical Fitness survey, a health surveillance survey for Chinese school-age students, was conducted six times during 1985–2014. In 2013, more than 120,000 students aged 7–18 years were selected from seven major geographic areas in China using stratified random cluster sampling. Overweight and obesity were prevalent in 12.2% and 7.1% of these children, respectively. Furthermore, the prevalence rates of overweight and obesity in this group also showed an increase, being 11 and 56 times higher, respectively, in 2014 than in 1985. 3.6 Physical inactivity The results from the CHNS demonstrated a significant decline in overall physical activity (PA) in Chinese residents aged 18–60 years during 1991–2011. Such a decline was largely driven by occupational PA reduction. PA decreased by 31% from 382 metabolic equivalent of task (MET)-h/week in 1991 to 264 MET-h/week in 2011 among adult men and by 42% from 420 MET-h/week to 243 MET-h/week among adult women. The number of participants (including children and adolescents) engaging in regular PA increased by 5.7% in 2014 compared with that in 2007 (33.9% vs. 5.7%). However, the rate of regular PA participants was still low among young adults aged 20–49 years. The 6th National Physical Fitness study, a health surveillance survey of Chinese school students, was conducted among more than 220,000 students aged 9–22 years in 2014. The results showed that the prevalence of PA time 40 years. The most significant contributor to stroke was hypertension, followed by family history, dyslipidemia, atrial fibrillation, diabetes, physical inactivity, smoking, and obesity. The incidence of first-ever stroke in adults aged 40–74 years increased at an annual rate of 8.3%, from 189/100,000 in 2002 to 379/100,000 in 2013. The mortality of stroke in adults aged 40–74 years remained stable during 2002–2013, at approximately 124/100,000. 4.2 Coronary heart disease According to data from the China Health and Family Planning Statistics Yearbook (2017), the mortality of CHD in 2016 was still increasing in both urban and rural areas (Figure 5). It was 113.46/100,000 for urban and 118.74/100,000 for rural residents. Overall, the mortality rate of CHD was higher in men than in women and higher in rural areas than in urban areas. Figure 5. Mortality rates due to cardiovascular disease in urban and rural areas in China: 2002–2016. Acute myocardial infarction (AMI) mortality increased between 2002 and 2016, with a rapid increase observed from 2005 onwards. AMI mortality in rural areas exceeded that in urban areas in 2007, 2009, and 2011, markedly increased in 2012, and significantly exceeded that in urban areas in 2013 and 2016 (Figure 6). Mortality from AMI increased with age regardless of sex or urban/rural distinction and increased most significantly after the age of 40 years. Figure 6. Mortality rates due to acute myocardial infarction in urban and rural areas in China: 2002–2016. 4.3 Heart rhythm disorders A 2004 survey of 19,363 participants aged ≥ 35 years from 10 different regions in China (four towns and six rural areas) showed that the age-adjusted prevalence of atrial fibrillation (AF) was 0.77% (0.78% for men and 0.76% for women). A stratified multi-stage random sampling survey of 31,230 community residents in 31 provinces, municipalities, and autonomous regions of mainland China showed that AF was prevalent in 0.71% of adults aged ≥ 35 years. The application of radiofrequency catheter ablation (RFCA) increased during 2010–2017 at an annual rate of 13.2%–17.5%. The number of RFCAs performed reached up to 133,900 in 2017. Among all patients undergoing RFCA, the proportion of those who underwent RFCA for AF increased annually from 21.0% in 2015 to 23.1% in 2016 and 27.3% in 2017. Statistics from the National Health Commission's online registration system show that 76,717 pacemakers were implanted in 2017, with an increase of 4.98% over the previous year. The proportion of dual-chamber pacemakers implanted was approximately 73%, with an increase of 4% compared with the data from 2016. The number of implantable cardioverter-defibrillator (ICD) implantations has been increasing continuously in recent years at an annual growth rate of > 10%. In 2017, 4092 ICDs were implanted, and the proportions of single- and dual-chamber ICD implantations were 37.7% and 62.3%, respectively, with little variation from the values in 2016. The proportions of ICD implantation for primary and secondary prevention were 44.5% and 55.5%, respectively. In total, 4138 cardiac resynchronization therapies (CRTs) were performed in 2017, an increase of 29.3% and 16.2% compared with that in 2016 and 2015, respectively. The rate of CRT-D implantation was also observed to be increasing yearly. 4.4 Heart failure A survey of 15,518 people from 20 urban and rural areas in 10 provinces in China demonstrated that in 2000, chronic HF was prevalent in 0.9% of the Chinese population aged 35–74 years (0.7% in men and 1.0% in women). The prevalence was higher in the north than in the south (1.4% vs. 0.5%) and higher in urban areas than in rural areas (1.1% vs. 0.8%). The prevalence of HF increased significantly with age. The China Heart Failure Registry Study (China-HF)[12] analyzed clinical data from 8516 patients with HF during 2012–2014. The results showed an upward trend in the average age of hospitalized patients with HF. Hypertension and CHD had become the main causes of HF in China, and infection was the most common trigger of HF. The mortality of hospitalized patients with HF was 4.1%, which was significantly lower than those reported in previous studies. 4.5 Pulmonary disease The China Pulmonary Health study evaluated 50,991 participants who had reliable post-bronchodilator results between June 2012 and May 2015. The results showed that the prevalence of COPD was 8.6%,[3] accounting for 99.9 million people with COPD in China. The National Cooperative Project for the Prevention and Treatment of Venous Thromboembolism conducted a registry study during 1997–2008. They evaluated 16,972,182 patients with pulmonary embolism (PE) admitted to any of the > 60 Grade-III Class-A hospitals and found an annual PE incidence of 0.1%.[14] 4.6 Cardiovascular Surgery In 2017, 228,938 cardiac surgeries were performed in mainland China. Of these, 162,597 were performed on-pump, accounting for 71% of such surgeries. In the same year, 77,305 operations for congenital heart diseases, 65,749 surgical inventions for valvular heart diseases, 45,455 coronary artery bypass grafts, and 19,585 aortic surgeries were performed in mainland China and Hong Kong, with 2002 patients supported by extracorporeal membrane oxygenation. The number of heart transplants in China has been increasing for the past 10 years. In 2017, 559 heart transplants were completed, and 32,126 patients with congenital heart disease were treated with interventional therapy in mainland China. The overall success rate was 98.6%. According to the 2011 China Health Insurance Research data, the annual incidence of acute aortic dissection in mainland China was approximately 2.8/100,000. The incidence was significantly higher in men than in women (3.7/100,000 vs. 1.5/100,000, P 18 years. The prevalence of estimated glomerular filtration rate 30 mg/g was 9.4%, implying that approximately 120 million individuals in China had CKD. According to the annual report from China Kidney Disease Network,[16] CVD is present in 27.8% of hospitalized patients with CKD, with CHD being the most common CVD (17.7%), followed by HF (13.0%) and stroke (9.2%). 4.8 Peripheral arterial disease Lower extremity atherosclerotic disease (LEAD) is common among the middle-aged and older population. The major cause of LEAD is atherosclerosis. Cerebrovascular disease and IHD are present in 30% and 25% of patients with LEAD, respectively. The prevalence of LEAD varies widely among different populations, ranging from 2.1% to 27.5%. The China National Stroke Prevention Project reported that 84,880 residents aged ≥ 40 years from 31 provinces, municipalities, and autonomous regions of mainland China underwent carotid ultrasonography. The overall prevalence of carotid atherosclerosis was 36.2%. Approximately 26.5% of participants had increased intima-media thickness (≥ 1 mm), and 13.9% presented plaques. The Taiwanese Healthcare Insurance program reported that the incidence of renal vascular disease in the overall population of 23 million was 6.69/100,000 person-years. The temporal trend in incidence decreased annually from 2000, and this was mainly attributed to the decline in the incidence of renal artery stenosis among the middle-aged and older population. Further, such decrease was consistent with the increased control rate of atherosclerosis in Taiwan.[17] 4.9 Assessment of medical care quality for CVD Although the quality of medical care for CVD in China has rapidly improved in recent years, some shortcomings remain to be addressed. The China Patient-centered Evaluative Assessment of Cardiac Events study demonstrated that among patients with AMI, the percentage of evidenced-based medication and percutaneous coronary interventions according to the Chinese Society of Cardiology guideline recommendations increased in 2011 compared with that in 2001. Meanwhile, the percentage of thrombolysis decreased. The in-hospital mortality did not markedly decrease due to delayed visit time and a low reperfusion rate.[18] 5 Community-based prevention and control of CVD In China, the community-based management of CVD has been investigated and implemented for the last 40 years. With a national comprehensive intervention strategy for the prevention and control of hypertension, the community-based management of CVD in China is moving forward from the process of exploration and has achieved notable success. A low-cost comprehensive intervention study was conducted in patients with hypertension from rural areas in Fuxin City, Liaoning Province, with each village considered as a unit. Patients were randomly divided into three groups: the health education group, the elementary intervention group, and the comprehensive intervention group. The aim was to explore the effect of comprehensive intervention on the reduction in CV events. By the end of the 15-month follow-up, the mean blood pressure decreased by 16.07/9.42 mmHg, and the rate of hypertension control increased significantly from 1.1% at baseline to 33.1%. The total risk of CVD and stroke was 55.9% and 55.2% lower in the medication group than in the health education group, respectively. 6 Medical treatment and expenditure on CVD The number of patients with CVD or diabetes discharged from hospitals in China has been increasing since 1980. Correspondingly, the total expenditure on hospitalization for CVD has also increased rapidly. In 2016, 20.0219 million patients with CVD were discharged from hospitals, accounting for 12.57% of the total number of discharges during this period. Among the discharged patients, 10,026,300 had heart diseases, accounting for 6.30% of this group, whereas 9,995,600 had cerebrovascular disease, accounting for 6.27%. Among the discharged patients with CVD, IHD (7,382,400) and cerebral infarction (6,403,000) were the leading causes of hospitalizations, accounting for 36.87% and 31.98% of all admissions, respectively. Other causes included hypertension (2,407,000) and intracranial hemorrhage (1,429,100). From 1980 to 2016, the average annual growth rate in the number of discharged CVD patients in China was 9.85%, higher than that for the number of patients discharged overall (6.33%) during this period. Among the various CVDs, cerebral infarction (12.16%) showed the highest annual average growth rate, followed by IHD (11.42%), AMI (10.73%), intracranial hemorrhage (9.48%), hypertension (7.45%), hypertensive heart disease and kidney disease (5.77%), and rheumatic heart disease (1.20%). Meanwhile, the annual average growth rate for diabetes was 13.59% during 1980–2016. In 2016, the hospitalization cost was 19.085 billion RMB for AMI, 25.419 billion RMB for intracranial hemorrhage, and 60.105 billion RMB for cerebral infarction. The average annual growth rates of hospitalization cost for these three major CVDs from 2004 onwards were 29.15%, 16.88%, and 22.24%, respectively. In 2016, the average cost of each hospitalization for AMI, intracranial hemorrhage, and cerebral infarction was 26056.9, 17787.0, and 9387.0 RMB, respectively, showing annual growth rates of 7.12%, 5.90%, and 2.30%. 7 Conclusions The National Center for Cardiovascular Diseases of China continuously monitors and evaluates sources of data on cardiovascular disease in China to provide the most current information annually. This annual report is the product of the effort of numerous physicians, scientists and government professional. Their contributions are gratefully appreciated. Figure 7. Trend of hospitalization expenses for CVD in China: 2004–2015. AMI: acute myocardial infarction; CVD: cardiovascular disease.

0 comments Cited 164 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion.

H Kin, Ning Wang, Faraz Kerendi … (2004)

We previously showed that brief intermittent ischemia applied during the onset of reperfusion (i.e., postconditioning) is cardioprotective in a canine model of ischemia-reperfusion. This study tested the hypothesis that the early minutes of reperfusion (R) during which postconditioning (Post-con) is applied are critical to its cardioprotection. In anesthetized open-chest rats, the left coronary artery (LCA) was occluded for 30 min and reperfused for 3 h. All rats were randomly divided into six groups: Control (n=8): no intervention at R; Ischemic preconditioning (IPC) (n=8): the LCA was occluded for 5 min followed by 10 min of R before the index occlusion; Post-con 1 (n=8): after LCA occlusion, three cycles of 10 s R followed by 10 s LCA re-occlusion were applied during the first minute of R; Post-con 2 (n=8): Six cycles of 10 s R and 10 s re-occlusion were applied during the first 2 min of R; Delayed Post-con (n=8): the ligature was loosened for full reflow for the first minute of R, after which the three-cycle Post-con algorithm was applied; Sham (n=6): the surgical procedure was identical to other groups, but the LCA ligature was not ligated. Infarct size (TTC staining) was 23% smaller in Post-con 1 (40+/-2%*) than in Control (52+/-3%), confirmed by plasma creatine kinase activity (18+/-2* vs. 46+/-6 IU/g protein). There was no further reduction in infarct size with 6 cycles of Post-con (40+/-2.9%, p>0.05 vs. Post-con 1). Meanwhile, infarct size reduction was significantly greater in the IPC group (17+/-3%) than in Post-con1 (p<0.01). The plasma lipid peroxidation product malondialdehyde (MDA, microM/ml) was less after R in IPC and Post-con 1 (0.8+/-0.07* and 0.8+/-0.06*) vs. Control (1.21+/-0.08), consistent with a visual decrease in superoxide anion generation (dihydroethidium staining) in the AAR myocardium after 3 h of reperfusion. Neutrophil accumulation (myeloperoxidase activity, MPO, U/100 g tissue) in the AAR was less in IPC (1.4+/-0.3*) and Post-con 1 (2.5+/-0.3*) vs. Control (5.5+/-0.6). The reductions in infarct size, creatine kinase, MDA and DHE staining were lost with delayed Post-con, while MPO activity remained lower than in Control (3.2+/-0.4*). (1) Post-con at onset of R reduces myocardial injury; (2) cardioprotection may be mediated, in part, by inhibiting oxidant generation and oxidant mediated injury; (3) the first minute of R in the rat model is critical to cardioprotection by Post-con; and (4) cardioprotection by Post-con may be independent of neutrophil accumulation in AAR. *p<0.05 Post-con vs. Control.

0 comments Cited 71 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction.

Kenji Imai, TETSUYA AMANO, Toyoaki Murohara … (2005)

Intravenous nicorandil, a hybrid compound of ATP-sensitive potassium channel opener and nitric oxide donor, has been reported to ameliorate early functional and clinical problems in patients with acute myocardial infarction. However, its effects on the late phase remain unclear. This follow-up study to 5 years of a randomized, double-blinded trial was conducted among 368 patients with first ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention (PCI). They were randomly assigned to receive 12 mg of nicorandil or a placebo intravenously just before reperfusion. We analyzed incidence of cardiovascular death or rehospitalization for congestive heart failure after PCI as well as various aspects of epicardial flow and microvascular function. Mean follow-up was 2.4 years (SD, 1.4). A total of 12 (6.5%) patients receiving nicorandil and 30 (16.4%) receiving placebo had cardiovascular death or hospital admission for congestive heart failure (hazard ratio, 0.39; 95% CI, 0.20 to 0.76; P=0.0058). Postprocedural TIMI 3 flow was obtained in 89.7% of the nicorandil group and in 81.4% of the placebo (hazard ratio, 1.99; 95% CI, 1.09 to 3.65; P=0.025). Corrected TIMI frame count was furthermore lower in the nicorandil group (21.0+/-9.1 versus 25.1+/-14.1; P=0.0009). ST-segment resolution >50% was observed in 79.5% and 61.2% of the nicorandil and placebo groups, respectively (hazard ratio, 2.45; 95% CI, 1.54 to 3.90; P=0.0002). The addition of intravenous nicorandil to PCI leads to beneficial clinical outcomes and prevents cardiovascular events of long duration and death in patients with ST-segment-elevation myocardial infarction.

0 comments Cited 38 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Geng QIAN

Yun-Dai CHEN

Journal

Journal ID (nlm-ta): J Geriatr Cardiol

Journal ID (iso-abbrev): J Geriatr Cardiol

Journal ID (publisher-id): JGC

Title: Journal of Geriatric Cardiology : JGC

Publisher: Science Press (Beijing, China )

ISSN (Print): 1671-5411

Publication date (Print): August 2020

Publication date (Electronic, pub): 28 August 2020

Volume: 17

Issue: 8

Pages: 519-524

Affiliations

[1 ] Department of Cardiology, the First Medical Center of Chinese PLA General Hospital, Beijing, China

[2 ] The School of Medicine, Nankai University, Tianjin, China

[3 ] Department of Cardiology, the First People's Hospital of Yunlin, Guangxi, China

[4 ] Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China

[5 ] Department of Cardiology, Wuhan Asia Heart Hospital, Wuhan, China

[6 ] Department of Cardiology, Hainan Hospital of PLA General Hospital, Hainan, China

[7 ] Department of Cardiology, Affiliated Hospital of Zunyi Medical College, Guizhou, China

[8 ] Department of Cardiology, Guizhou Provincial People's Hospital, Guizhou, China

[9 ] Department of Cardiology, the Second Hospital of Hebei Medical University, Hebei, China

[10 ] Department of Cardiology, the Second Affiliated Hospital of Nanchang University, Jiangxi, China

Author notes

Geng QIAN, Department of Cardiology, the First Medical Center of Chinese PLA General Hospital, Beijing, China. E-mail: qiangeng 9396@ 123456263.net

Yun-Dai CHEN, Department of Cardiology, the First Medical Center of Chinese PLA General Hospital, Beijing, China. E-mails: cyundai@ 123456vip.163.com

Article

Publisher ID: jgc-17-8-519

DOI: 10.11909/j.issn.1671-5411.2020.08.002

PMC ID: 7475214

SO-VID: 4dcc6e1c-5709-4fcc-b8c5-771d5c4c72db

License:

This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/

History

Date received : 3 June 2020

Date revision received : 10 July 2020

Date accepted : 25 July 2020

Comments

Comment on this article

scite_

Cited by 1

Effects of Nicorandil Administration on Infarct Size in Patients With ST‐Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The CHANGE Trial
Authors: Geng Qian, Ying Zhang, Wei Dong …

See all cited by

Most referenced authors 279

See all reference authors

Effects of nicorandil on myocardial infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: study design and protocol for the randomized controlled trial

Read this article at

Abstract

Related collections

Cardiovascular Innovations and Applications

Most cited references 13

China cardiovascular diseases report 2018: an updated summary

Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion.

Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction.

Author and article information

Contributors

Journal

Affiliations

Author notes

Article

History

Categories

Comments

Comment on this article

Similar content 539

Cited by 1

Most referenced authors 279